Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial

Saroglitazar is a dual PPAR-α/γ agonist approved for the treatment of diabetic dyslipidemia. In addition to reduction in atherogenic lipids, it may also contribute to improvement in insulin sensitivity through PPAR-α/γ agonism, which remains unexplored. We conducted a randomized, double-blind, place...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Nimisha, Bhansali, Shobhit, Kurpad, Anura V., Hawkins, Meredith, Sharma, Akhilesh, Kaur, Sandeep, Rastogi, Ashu, Bhansali, Anil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908698/
https://www.ncbi.nlm.nih.gov/pubmed/31831868
http://dx.doi.org/10.1038/s41598-019-55466-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908698/
https://www.ncbi.nlm.nih.gov/pubmed/31831868
http://dx.doi.org/10.1038/s41598-019-55466-3

Ejemplares similares